DECREASED EXPRESSION OF THE SPECKLE-TYPE POZ PROTEIN IS ASSOCIATED WITH POOR PROGNOSIS IN BLADDER CANCER

Ma Junhong,Li Shengwen

2018-01-01

Acta medica mediterranea

Abstract:Introduction: Bladder cancer is one of the most common malignancies in the genitourinary system, and the incidence tends to increase year by year. Despite tremendous progress in diagnosis and traditional treatment, the prognosis of patients, especially locally advanced or muscle-invasive bladder cancer remains poor. Currently many molecular biomarkers are considered to be assoisated with the occurrence of bladder cancer. The Speckle-type POZ protein, SPOP, is an E3 ubiquitin ligase adaptor, and it is found to inhibit oncogenic signaling in other cancers. However, the molecular mechanisms in bladder cancer are less reported. Methods: In this study, we characterized the expression of SPOP in 46 pairs of bladder cancer tissues and adjacent tissues by immunohistochemical staining and Western blotting. The relationship between SPOP expression and clinicalpathologic factors was analyzed. Transfected bladder cancer cell lines T24 were used in cell viability, migration and wound healing assays to investigate the role of tumor suppression mechanism. Results: Immunohistochemical staining of SPOP can be detected in bladder cancer tissues but much less than adjacent bladder tissues (P < 0.01). High SPOP expression is negatively correlated with lymph node metastasis, poor histological differentiation, and tumor malignancy according to TAM staging. In vitro inhibition of SPOP markedly promoted cell viability, migration and invasion in vitro in bladder cancer cell lines. Likewise, overexpression of SPOP inhibited cell viability; migration and proliferation. Conclusions: Our findings indicate that SPOP might act as a tumor suppressor and may have potential use as novel biomarker of bladder cancer, and can provide an alternative strategy for developing therapeutic agents of bladder cancer in future.